Sound Energy #SOU provides an update on a potential farm-in and operational progress in Morocco Watch Now

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.25
Bid: 8.00
Ask: 8.50
Change: 0.00 (0.00%)
Spread: 0.50 (6.25%)
Open: 8.25
High: 8.25
Low: 8.00
Yest. Close: 8.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

ValiRx secures 'substantial amendment' to VAL201 clinical trials

Thu, 20th Jun 2019 09:54

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

The AIM-traded firm said that, following the approval of the amendment, prostate cancer specialist Dr Mark Linch had been appointed as principal investigator to the clinical trial team at University College London Hospital (UCLH).

Dr Linch was an honorary senior lecturer at the University College London (UCL) Cancer Institute, where he was leading the uro-oncology biology group, and was also a consultant medical oncologist specialising in the treatment of prostate and bladder cancer at UCLH.

ValiRx confirmed that Dr Rebecca Kristeleit was continuing with the study as chief investigator.

It said that to date, the results generated by the trial - aided by sizable analytical method developments - had shown that safe toxicological limits could be significantly elevated and applied to much higher levels in humans than was suggested by the preclinical studies.

The approval given to relax the restrictions previously applied to the trial would mean that a more effective use of VAL201 could be achieved with respect to concentration and timing, and regarding increased flexibility in the administration of the drug, the board explained.

Additionally, it said the amendment relating to dosing strategies meant that - in light of accumulated clinical data - the company would be able to develop further protocols.

Those would be designed to evaluate a range of defined therapeutic approaches that were to be tested against each other, to determine the most effective approach in terms of disease management, cost effectiveness and patient welfare in further clinical trials.

The protocols would be the precursor to seeking approval to conduct trials aimed at gaining sufficient data to secure partnering and then marketing approval application.

ValiRx reported that the trial thus far had met all of its primary and secondary endpoints, with the safety and tolerability results continuing to be acceptable, and further evidence of the compound's positive effect in reducing the progress of prostate cancer witnessed.

The data from the trial was currently being collated for examination by independent third party experts.

ValiRx said the approval of the amendment further validated its clinical development throughout VAL201's first-in-human trial.

Further information connected to the data, and the results and findings from the trial, would form the basis of a report outlining the compound's clinical profile and behaviour, which would be published in due course.

"This substantial amendment has taken a lot of effort from the whole team both internal and by all our service providers to achieve," said ValiRx chief operating officer Dr George Morris.

"The most gratifying thing is that our original pre-clinical experimental data has held up well and been vindicated throughout the whole of this first-in-human trial.

"Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."

More News

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

24 Jul 20 17:23

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

23 Jul 20 18:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

16 Jul 20 15:57

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

6 Jul 20 18:19

ValiRx looks to build on portfolio of drug candidates

(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.

6 Jul 20 09:31

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

1 Jul 20 13:10

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

16 Jun 20 13:58

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Delays Annual Results Amid Covid-19 Pandemic

8 Jun 20 15:39

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

2 Jun 20 12:57

ValiRx enters collaboration agreement for Covid-19 treatment

(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.

2 Jun 20 12:03

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

29 May 20 15:02

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

29 May 20 12:59

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

27 May 20 14:20

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

7 May 20 14:45

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

4 May 20 16:18

Login to your account

Don't have an account? Click here to register.